Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 21 Jul 2021 |
| Major Shareholder Announcement | 21 Jul 2021 |
| Genmab A/S has published its Articles of Association | 7 Jul 2021 |
| Capital Increase in Genmab as a Result of Employee Warrant Exercise | 6 Jul 2021 |
| Completion of share buy-back program | 1 Jul 2021 |
| Genmab A/S has published its Articles of Association | 1 Jul 2021 |